Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abemaciclib + necitumumab
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Abemaciclib + necitumumab is an investigational combination therapy consisting of two targeted agents for cancer treatment. Abemaciclib is a small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression in tumor cells. Necitumumab is a recombinant human IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting ligand binding and downstream signaling involved in tumor proliferation. This combination has been studied primarily in advanced non-small cell lung cancer (NSCLC) due to their non-overlapping toxicities and potential synergistic effects. However, clinical trials have not demonstrated significant additive efficacy over single-agent therapies[1][2][3]. The safety profile of the combination was consistent with those observed for each agent individually[1].
- Other names
- necitumumab + abemaciclib
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on abemaciclib + necitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abemaciclib + necitumumab.